How long after ayahuasca can you do ibogaine?

A minimum of two weeks after the last ayahuasca ceremony is the prudent baseline — confirmed with the ibogaine provider during medical screening. Ayahuasca contains MAOIs (harmine and harmaline from the Banisteriopsis caapi vine), which are an absolute contraindication for ibogaine. Combining them creates conditions for serotonin syndrome, which can be fatal. The acute pharmacological activity of harmine clears faster than SSRIs, but the washout period must be confirmed with the provider.

Which is better for addiction — ayahuasca or ibogaine?

For opioid dependence, ibogaine has the stronger evidence base. It engages opioid receptors directly and interrupts withdrawal at the neurological level — a mechanism ayahuasca does not replicate. The 2023 Stanford study documented 88% reductions in PTSD symptoms at one month in 30 treatment-resistant veterans with significant substance use histories. For addiction where trauma is the primary driver, ayahuasca addresses the psychological layer. They address different components of the same problem.

Can you do ayahuasca and ibogaine together?

Not simultaneously. The pharmacological interaction between MAOIs (present in ayahuasca) and ibogaine creates conditions for serotonin syndrome. In sequence, with adequate washout periods and integration work in between, some practitioners work with both medicines. The sequencing and timing must be discussed with both providers. Never combine them in the same period without explicit medical guidance.

Is ibogaine stronger than ayahuasca?

They are intense in different ways. Ibogaine is longer — 12–24 hours — and more physically demanding throughout. Ayahuasca is shorter — 4–6 hours — but can produce significant emotional and perceptual intensity within that window. The concept of one being 'stronger' does not map accurately to what these compounds produce. They address different things through different mechanisms.

Who should not do ibogaine?

Absolute contraindications include QT prolongation or significant cardiac arrhythmia on EKG; current SSRIs or SNRIs without a completed physician-supervised taper; recent MAOI use including ayahuasca without adequate washout; lithium; methadone without a specific transition protocol; active psychosis or schizophrenia-spectrum disorder; severe liver or kidney disease; and pregnancy. Someone in acute psychiatric crisis is not an appropriate candidate at this time.

Is ibogaine legal in Canada?

Ibogaine is not listed under Canada's Controlled Drugs and Substances Act — it is not explicitly prohibited. This places it in a legally distinct position from the US (Schedule I since 1970) and UK (Class A). Providers in Vancouver, BC operate openly. The legal status does not reduce the clinical requirements: EKG screening, on-site physician, and continuous cardiac monitoring are necessary regardless of where the provider operates.

How much does ibogaine ceremony cost in Vancouver?

At Transcend in Vancouver, iboga ceremony costs $2,000–$5,000 CAD. This covers an on-site medical professional throughout the 12–24 hour active experience, continuous cardiac ECG monitoring, whole-plant root bark, facilitation, and 2–3 days of supervised recovery. Integration coaching — $150–$300 CAD per session — is separate. Providers charging significantly less are removing safety infrastructure. The cost of a physician present for 12–24 hours is real.

Ayahuasca vs Ibogaine: How They Differ — and When Each Is the Wrong Choice | Transcend

Ayahuasca vs ibogaine is not a question of preference. They work through different pharmacological systems, last different lengths of time, and address different conditions most effectively. Treating them as alternatives to each other produces poor outcomes. More consequentially: ayahuasca contains MAOIs, and MAOIs are an absolute contraindication for ibogaine. Anyone who has taken ayahuasca recently and is considering ibogaine needs to understand this before doing anything else.

Ayahuasca is a DMT-containing brew that produces a 4–6 hour visionary experience through serotonin receptor agonism. Ibogaine is an alkaloid from Tabernanthe iboga that produces a 12–24 hour autobiographical experience through simultaneous engagement of opioid, serotonin, NMDA, and sigma receptors. They address different conditions. They are not substitutes.

Dense jungle canopy seen from below — ayahuasca and ibogaine both originate from plants used ceremonially; they work through different mechanisms and address different conditions — Photo by Liger Pham via Pexels

How each medicine works

Ayahuasca is prepared by combining the Banisteriopsis caapi vine — which contains beta-carboline alkaloids (harmine, harmaline) that function as MAOIs — with a DMT-containing plant, most commonly Psychotria viridis. The MAOIs prevent the enzymatic breakdown of DMT in the gut, allowing it to reach the brain. Without the vine, oral DMT is inactive. The primary pharmacological mechanism is serotonergic: DMT is a potent agonist at 5-HT2A receptors, a binding profile shared with psilocybin and LSD.

Ibogaine is the primary psychoactive alkaloid of Tabernanthe iboga root bark, used ceremonially by the Bwiti peoples of Central Africa for centuries. Its pharmacology does not fit any existing drug category. It acts simultaneously on mu-opioid receptors, the serotonin transporter (SERT), NMDA receptors, and sigma-2 receptors — binding profiles that do not overlap significantly with ayahuasca. Critically, it triggers upregulation of GDNF (glial cell line-derived neurotrophic factor), a neuroplasticity protein depleted in addiction-related and PTSD-related dopamine pathways. Ayahuasca has no equivalent mechanism.

After the active ceremony, ibogaine converts to noribogaine in the body. Noribogaine remains biologically active for weeks to months, continuing to interact with serotonin and opioid receptors — the most plausible explanation for why ibogaine's therapeutic effects persist long beyond the ceremony itself. For a detailed look at the mechanism, the guide to how ibogaine works covers the receptor pharmacology and GDNF evidence.

Misty forest path at dawn — ibogaine produces a 12–24 hour autobiographical experience through multi-system neurological engagement including GDNF upregulation — Photo by Pixabay via Pexels

What the experience is like

Duration alone is significant: ibogaine produces an active pharmacological experience lasting 12–24 hours. Ayahuasca lasts 4–6 hours. Both are demanding. They demand different things.

Ayahuasca's content tends to be visionary and symbolic — imagery, archetypes, emotional material arriving through a medium of altered visual and perceptual experience. The confrontation it produces is real but arrives through metaphor. Understanding what arose requires interpretive work during and after ceremony. Many people return for multiple ayahuasca ceremonies over years, working through different material in each.

Ibogaine's content is primarily autobiographical. People consistently describe extended review of their actual life — specific memories, specific relationships, the patterns of decision and avoidance that produced where they are — without the emotional charge that normally makes those memories difficult to access directly. What the medicine shows is literal, not symbolic. The physical experience throughout is demanding: nausea, ataxia, sensitivity to light and sound, inability to sleep. The person is largely immobile for the duration. It does not resemble ayahuasca, psilocybin, or any short-duration compound. The active experience runs 12–24 hours and tends to surprise people regardless of what they have read beforehand.

These are not interchangeable experiences. They address different layers of material through different means.

What each medicine addresses most effectively

For opioid dependence, ibogaine has the stronger evidence base — by a significant margin. It engages the opioid receptor system directly, substantially interrupts withdrawal, and resets receptor sensitivity. Ayahuasca does not produce the same neurological interruption. This is not a criticism of ayahuasca; it is simply not its mechanism.

The 2023 Stanford study published in Nature Medicine examined 30 special operations veterans with treatment-resistant PTSD, traumatic brain injury, and depression — most of whom had significant histories of substance use. At one month post-treatment: PTSD symptoms decreased by an average of 88%. Depression decreased by 87%. Anxiety by 81%. These were not people who had not tried other approaches. They had. The results were not incremental.

Conventional antidepressant research considers a 50% reduction in depression scores a strong response. That context matters when reading those numbers. The study has genuine limitations — 30 participants, no placebo arm — that do not change the direction of the finding. Texas subsequently committed $50 million USD to clinical ibogaine trials at four universities.

Ayahuasca has a growing evidence base for depression, anxiety, and trauma — primarily through serotonergic mechanisms. Research from Brazil, Spain, and the United States shows consistent direction. Published clinical studies on ayahuasca have grown substantially since 2015. It is more commonly used as a sustained practice — multiple ceremonies over time — than as a single intervention. The research is developing; the direction is consistent.

The practical distinction: ibogaine is typically chosen when there is a specific treatment target — opioid dependence, treatment-resistant PTSD or depression — and where the neurological component of the condition is primary. Ayahuasca is more appropriate for ongoing emotional processing, or when the person is not dealing with a condition that requires neurological interruption at the receptor level. Integration support after either medicine is what determines whether the work produces lasting change. Providers who hand people a pamphlet and wish them luck after ceremony are not providing treatment — they are providing the medicine, which is a different thing.

Hands cradling a flame in darkness — the integration period after ceremony determines whether ibogaine or ayahuasca produces lasting change — Photo by Emre Can Acer via Pexels

The MAOI timing question

This is the most consequential practical issue for anyone who has done ayahuasca and is now considering ibogaine.

Ayahuasca contains MAOIs — harmine and harmaline from the Banisteriopsis caapi vine. MAOIs are an absolute contraindication for ibogaine. This is not a caution to weigh against potential benefit. It is a hard medical contraindication. MAOIs inhibit the enzymes that metabolise serotonin, dopamine, and other monoamines. Ibogaine inhibits the serotonin transporter. Combining them creates conditions for serotonin syndrome, which can be fatal.

Harmine and harmaline have acute half-lives of roughly 2–4 hours. The pharmacological activity clears faster than SSRIs. But the appropriate washout period before ibogaine is not measured in hours. A minimum of two weeks after the last ayahuasca ceremony is prudent — and should be confirmed directly with the ibogaine provider during medical screening. The ibogaine-then-ayahuasca sequence requires the same care: noribogaine remains active for weeks to months after ibogaine ceremony, and ayahuasca's MAOIs interact with the serotonergic activity that continues during that window.

Any ibogaine provider worth working with will ask about recent ayahuasca use as part of standard intake. If a provider does not ask — if the screening conversation does not reach this — that is information about how the provider operates. The detailed guide to ayahuasca and ibogaine interactions covers the pharmacology and sequencing more fully.

Who ibogaine is not for

The contraindications are non-negotiable:

QT prolongation or significant cardiac arrhythmia on EKG — ibogaine extends the QT interval. This is the mechanism behind ibogaine-related deaths when cardiac screening is skipped. Every legitimate provider runs a 12-lead EKG before any ceremony date is confirmed. Any provider who does not is not operating safely.
Current SSRIs or SNRIs without a completed physician-supervised taper — ibogaine inhibits the serotonin transporter; the combination creates serotonin syndrome risk. The most common antidepressants prescribed for PTSD and depression are SSRIs. The taper must be completed under physician supervision before any ceremony is possible.
Recent ayahuasca ceremony — see above. The MAOI content requires a washout period.
Lithium — an absolute contraindication.
Methadone — a medically supervised transition protocol is required before ibogaine is possible; this cannot be abbreviated.
Active psychosis or schizophrenia-spectrum disorder — ibogaine amplifies what is present; it is not a treatment for psychotic conditions.
Severe liver or kidney disease — ibogaine is hepatically metabolised; impaired liver function changes the pharmacokinetics in ways that are not safely predictable.
Pregnancy.

Someone in acute psychiatric crisis is not an appropriate candidate at this moment — regardless of how much they want access and regardless of how urgently they need something to change. The experience amplifies what is present. We tell people this directly and without softening it.

Is ibogaine appropriate for you?

The right question is not “ayahuasca or ibogaine” as though they were on a menu. The question is what you are actually dealing with, what has not worked so far, and whether ibogaine is the appropriate tool for that specific condition in your specific situation.

Ibogaine is appropriate for people with a specific treatment target — opioid dependence, treatment-resistant PTSD or depression — who have completed medical screening, who are prepared for a 12–24 hour physically demanding ceremony, and who have integration support in place for the weeks that follow. It is not appropriate as a first-line approach, not as a way of bypassing other work, and not for people primarily seeking an expansive or visionary experience. Iboga will show you what you have been avoiding. It is not designed to show you what you hope to find.

For people who have done ayahuasca and found it insufficient — who have done the symbolic and emotional work but need neurological intervention — ibogaine addresses a different layer of the same problem. The ibogaine vs ayahuasca comparison covers the mechanisms in more detail. If what you are reading sounds like a workable description of your situation, the starting point is a screening conversation — not a ceremony date.

At Transcend, every application receives a personal response within 2–3 business days. Medical screening determines candidacy. Ceremony comes after that. Apply here.

Frequently asked questions

What is the main difference between ayahuasca and ibogaine?: Ayahuasca is a DMT-containing brew that produces a 4–6 hour visionary experience through serotonin receptor agonism. Ibogaine is an alkaloid from iboga root bark that produces a 12–24 hour autobiographical experience through simultaneous engagement of opioid, serotonin, NMDA, and sigma receptors. The mechanisms, durations, and what each addresses most effectively are all different. They are not substitutes.
How long after ayahuasca can you do ibogaine?: A minimum of two weeks after the last ayahuasca ceremony — confirmed with the ibogaine provider during medical screening. Ayahuasca contains MAOIs (harmine, harmaline), which are an absolute contraindication for ibogaine. The acute pharmacological activity of harmine and harmaline clears relatively quickly, but prudent practice requires a washout period and direct confirmation with the provider. Do not abbreviate this.
Which is better for addiction — ayahuasca or ibogaine?: For opioid dependence specifically, ibogaine has the stronger evidence base. It engages opioid receptors directly and interrupts withdrawal at the neurological level — a mechanism ayahuasca does not replicate. The 2023 Stanford study found 88% reductions in PTSD symptoms in 30 treatment-resistant veterans, most of whom had significant substance use histories. For addiction where trauma is the primary driver and substance use is secondary, ayahuasca addresses the psychological layer. They are not competing for the same role.
Can you do ayahuasca and ibogaine together?: Not simultaneously. The pharmacological interaction between MAOIs and ibogaine creates serotonin syndrome risk. In sequence, with adequate washout periods and proper integration, some practitioners work with both — but the sequencing requires discussion with both providers. Never do both in the same period without explicit medical guidance.
Is ibogaine stronger than ayahuasca?: They are intense in different ways. Ibogaine is longer — 12–24 hours — and more physically demanding. Ayahuasca is shorter but can produce significant intensity within its 4–6 hour window. The concept of one being “stronger” does not map accurately to what these compounds produce. They address different things through different mechanisms.
Who should not do ibogaine?: Absolute contraindications include QT prolongation or significant cardiac arrhythmia; current SSRIs or SNRIs without a completed supervised taper; recent MAOI use including ayahuasca; lithium; methadone without a transition protocol; active psychosis or schizophrenia-spectrum disorder; severe liver or kidney disease; and pregnancy. Someone in acute psychiatric crisis is not an appropriate candidate at this time.
Is ibogaine legal in Canada?: Ibogaine is not listed under Canada's Controlled Drugs and Substances Act — it is not explicitly prohibited. This places it in a legally distinct position from the US (Schedule I) and UK (Class A). Providers in Vancouver, BC operate openly. This does not mean all providers operate safely — the clinical requirements (EKG, screening, on-site physician) apply regardless of legal status.
How much does ibogaine ceremony cost in Vancouver?: At Transcend in Vancouver, iboga ceremony costs $2,000–$5,000 CAD. This includes an on-site medical professional throughout the 12–24 hour active experience, continuous cardiac ECG monitoring, whole-plant root bark, facilitation, and a 2–3 day supervised recovery period. Integration coaching — $150–$300 CAD per session — is a separate service. Providers charging significantly less are removing safety infrastructure. The cost of a physician present for 12–24 hours is real.